New developments in the treatment of HER2-positive breast cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• GuyPMPlatkoJVCantleyLCCerioneRACarrawayKL3rdInsect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activityProc Natl Acad Sci U S A19949117813281368058768
   PubMed Web of Science ®Google Scholar
• Graus-PortaDBeerliRRDalyJMHynesNEErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingEMBO J1997167164716559130710
   PubMed Web of Science ®Google Scholar
• GhoshRNarasannaAWangSETrastuzumab has preferential activity against breast cancers driven by HER2 homodimersCancer Res20117151871188221324925
   PubMed Web of Science ®Google Scholar
• HolbroTBeerliRRMaurerFKoziczakMBarbasCF3rdHynesNEThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationProc Natl Acad Sci U S A2003100158933893812853564
   PubMed Web of Science ®Google Scholar
• KimHHSierkeSLKolandJGEpidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the ErbB3 gene productJ Biol Chem19942694024747247557929151
   PubMed Web of Science ®Google Scholar
• SoltoffSPCarrawayKL3rdPrigentSAGullickWGCantleyLCErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factorMol Cell Biol1994146355035587515147
   PubMed Web of Science ®Google Scholar
• EcclesSAThe role of c-erbB-2/HER2/neu in breast cancer progression and metastasisJ Mammary Gland Biol Neoplasia20016439340612013529
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• MabuchiSKawaseCAltomareDAmTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovaryClin Cancer Res200915175404541319690197
   PubMed Web of Science ®Google Scholar
• HudziakRMLewisGDWingetMFendlyBMShepardHMUllrichAp185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factorMol Cell Biol198993116511722566907
   PubMed Web of Science ®Google Scholar
• KumarRShepardHMMendelsohnJRegulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cellsMol Cell Biol19911129799861671297
   PubMed Web of Science ®Google Scholar
• PietrasRJFendlyBMChazinVRPegramMDHowellSBSlamonDJAntibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cellsOncogene199497182918387911565
   PubMed Web of Science ®Google Scholar
• PietrasRJPegramMDFinnRSManevalDASlamonDJRemission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene19981717223522499811454
   PubMed Web of Science ®Google Scholar
• CarterPPrestaLGormanCMHumanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci U S A19928910428542891350088
   PubMed Web of Science ®Google Scholar
• BaselgaJNortonLAlbanellJKimYMMendelsohnJRecombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsCancer Res19985813282528319661897
   PubMed Web of Science ®Google Scholar
• PegramMDSlamonDJCombination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivitySemin Oncol1999264 Suppl 12899510482199
   PubMed Web of Science ®Google Scholar
• SliwkowskiMXLofgrenJALewisGDHotalingTEFendlyBMFoxJANonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)Semin Oncol1999264 Suppl 12607010482195
   PubMed Web of Science ®Google Scholar
• NahtaRPharmacological strategies to overcome HER2 crosstalk and trastuzumab resistanceCurr Med Chem20121971065107522229414
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJHER2 therapy: molecular mechanisms of trastu-zumab resistanceBreast Cancer Res20068621517096862
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJHerceptin: mechanisms of action and resistanceCancer Lett2006232212313816458110
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJTrastuzumab: triumphs and tribulationsOncogene200726253637364317530017
   PubMed Web of Science ®Google Scholar
• NahtaRShabayaSOzbayTRoweDLPersonalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensCurr Pharmacogenomics Person Med20097426327420300449
   PubMedGoogle Scholar
• NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol20063526928016683005
   PubMedGoogle Scholar
• CuelloMEttenbergSAClarkASDown-regulation of the ErbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ErbB-2Cancer Res200161124892490011406568
   PubMed Web of Science ®Google Scholar
• GajriaDChandarlapatySHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Rev Anticancer Ther201111226327521342044
   PubMed Web of Science ®Google Scholar
• JunttilaTTAkitaRWParsonsKLigand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Cancer Cell200915542944019411071
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJRojoFArribasJBaselgaJTrastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res200161124744474911406546
   PubMed Web of Science ®Google Scholar
• LaneHAMotoyamaABBeuvinkIHynesNEModulation of p27/CDK2 complex formation through 4D5-mediated inhibition of HER2 receptor signalingAnn Oncol200112Suppl 1S21S2211521716
   PubMed Web of Science ®Google Scholar
• LeXFClaretFXLammayotAThe role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibitionJ Biol Chem200327826234412345012700233
   PubMed Web of Science ®Google Scholar
• IzumiYXuLdi TomasoEFukumuraDJainRKTumour biology: Herceptin acts as an anti-angiogenic cocktailNature2002416687827928011907566
   PubMed Web of Science ®Google Scholar
• ArnouldLGellyMPenault-LlorcaFTrastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?Br J Cancer200694225926716404427
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• BaselgaJTripathyDMendelsohnJPhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Clin Oncol19961437377448622019
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastu-zumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• EstevaFJValeroVBooserDPhase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerJ Clin Oncol20022071800180811919237
   PubMed Web of Science ®Google Scholar
• SeidmanADFornierMNEstevaFJWeekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationJ Clin Oncol200119102587259511352950
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• RusnakDWLackeyKAffleckKThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivoMol Cancer Ther200112859412467226
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ErbB2 and downstream ERK1/2 and AKT pathwaysOncogene200221416255626312214266
   PubMed Web of Science ®Google Scholar
• ZhouHKimYSPeletierAMcCallWEarpHSSartorCIEffects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistanceInt J Radiat Oncol Biol Phys200458234435214751502
   PubMed Web of Science ®Google Scholar
• ChuIBlackwellKChenSSlingerlandJThe dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancerCancer Res2005651182515665275
   PubMed Web of Science ®Google Scholar
• ZhangDPalABornmannWGActivity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cellsMol Cancer Ther2008771846185018644997
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecit-abine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol20102871124113020124187
   PubMed Web of Science ®Google Scholar
• ToiMIwataHFujiwaraYLapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and bio-marker results from Japanese patients phase II studiesBr J Cancer2009101101676168219844234
   PubMed Web of Science ®Google Scholar
• LinNUCareyLALiuMCPhase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200826121993199918421051
   PubMed Web of Science ®Google Scholar
• LinNUDiérasVPaulDMulticenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerClin Cancer Res20091541452145919228746
   PubMed Web of Science ®Google Scholar
• CappuzzoFBemisLVarella-GarciaMHER2 mutation and response to trastuzumab therapy in non-small-cell lung cancerN Engl J Med2006354242619262116775247
   PubMed Web of Science ®Google Scholar
• WangSENarasannaAPerez-TorresMHER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitorsCancer Cell2006101253816843263
   PubMed Web of Science ®Google Scholar
• NahtaRTakahashiTUenoNTHungMCEstevaFJP27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cellsCancer Res200464113981398615173011
   PubMed Web of Science ®Google Scholar
• MittendorfEAWuYScaltritiMLoss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesClin Cancer Res200915237381738819920100
   PubMed Web of Science ®Google Scholar
• NiikuraNLiuJHayashiNLoss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumorsJ Clin Oncol201230659359922124109
   PubMed Web of Science ®Google Scholar
• Price-SchiaviSAJepsonSLiPRat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistanceInt J Cancer200299678379112115478
   PubMed Web of Science ®Google Scholar
• NagyPFriedländerETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res200565247348215695389
   PubMed Web of Science ®Google Scholar
• HuangXGaoLWangSHeterotrimerization of the growth factor receptors ErbB2, ErbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to HerceptinCancer Res20107031204121420103628
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXZhangBKobayashiREstevaFJInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res20056523111181112816322262
   PubMed Web of Science ®Google Scholar
• RoweDLOzbayTBenderLMNahtaRNordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancerMol Cancer Ther2008771900190818645000
   PubMed Web of Science ®Google Scholar
• RitterCAPerez-TorresMRinehartCHuman breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkClin Cancer Res200713164909491917699871
   PubMed Web of Science ®Google Scholar
• ShattuckDLMillerJKCarrawayKL3rdSweeneyCMet receptor contributes to trastuzumab resistance of HER2-overexpressing breast cancer cellsCancer Res20086851471147718316611
   PubMed Web of Science ®Google Scholar
• JoshiJPBrownNEGrinerSENahtaRGrowth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cellsBiochem Pharmacol20118291090109921803025
   PubMed Web of Science ®Google Scholar
• KimKKLeeJJYangYYouKHLeeJHMacrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cellsCarcinogenesis200829470471218258606
   PubMed Web of Science ®Google Scholar
• ParkYJLeeHLeeJHMacrophage inhibitory cytokine-1 transacti-vates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cellsBMB Rep2010432919620193126
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXDuYEstevaFJLapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signalingMol Cancer Ther20076266767417308062
   PubMed Web of Science ®Google Scholar
• YakesFMChinratanalabWRitterCAKingWSeeligSArteagaCLHerceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor actionCancer Res200262144132414112124352
   PubMed Web of Science ®Google Scholar
• KuteTLackCMWillinghamMDevelopment of Herceptin resistance in breast cancer cellsCytometry A2004572869314750129
   PubMedGoogle Scholar
• CardosoFDurbecqVLaesJFBortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic mannerMol Cancer Ther20065123042305117148762
   PubMed Web of Science ®Google Scholar
• Esparís-OgandoAOcañaARodríguez-BarruecoRFerreiraLBorgesJPandiellaASynergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cellsAnn Oncol200819111860186918641009
   PubMed Web of Science ®Google Scholar
• TsengPHWangYCWengSCOvercoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitorMol Pharmacol20067051534154116887935
   PubMed Web of Science ®Google Scholar
• CrawfordANahtaRTargeting Bcl-2 in Herceptin-resistant breast cancer cell linesCurr Pharmacogenomics Person Med20119318419022162984
   PubMedGoogle Scholar
• MartinAPMitchellCRahmaniMNephewKPGrantSDentPInhibition of Mcl-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagyCancer Biol Ther20098212084209619823038
   PubMed Web of Science ®Google Scholar
• WittersLMWitkoskiAPlanas-SilvaMDBergerMVialletJLiptonASynergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitorOncol Rep200717246546917203189
   PubMed Web of Science ®Google Scholar
• CittellyDMDasPMSalvoVAFonsecaJPBurowMEJonesFEOncogenic HER2∆16 suppresses miR-15a/16 and deregulates Bcl-2 to promote endocrine resistance of breast tumorsCarcinogenesis201031122049205720876285
   PubMed Web of Science ®Google Scholar
• KumarRMandalMLiptonAHarveyHThompsonCBOverex-pression of HER2 modulates Bcl-2, Bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cellsClin Cancer Res199627121512199816290
   PubMed Web of Science ®Google Scholar
• MitraDBrumlikMJOkamgbaSUAn oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistanceMol Cancer Ther2009882152216219671734
   PubMed Web of Science ®Google Scholar
• SiddiqaALongLMLiLMarciniakRAKazhdanIExpression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathwaysBMC Cancer2008812918454859
   PubMed Web of Science ®Google Scholar
• ValabregaGCapelleroSCavalloniGHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibBreast Cancer Res Treat20111301294021153051
   PubMed Web of Science ®Google Scholar
• GojoIZhangBFentonRGThe cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1Clin Cancer Res20028113527353812429644
   PubMed Web of Science ®Google Scholar
• MitchellCYacoubAHosseinHInhibition of Mcl-1 in breast cancer cells promotes cell death in vitro and in vivoCancer Biol Ther201010990391720855960
   PubMed Web of Science ®Google Scholar
• NahtaRIglehartJDKempkesBSchmidtEVRate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and flavopiridolCancer Res20026282267227111956082
   PubMed Web of Science ®Google Scholar
• NahtaRTrentSYangCSchmidtEVEpidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancerCancer Res200363133626363112839951
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6 K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol201017741647165620813970
   PubMed Web of Science ®Google Scholar
• LuCHWyszomierskiSLTsengLMPreclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiencyClin Cancer Res200713195883588817908983
   PubMed Web of Science ®Google Scholar
• OzbayTDurdenDLLiuTO’ReganRMNahtaRIn vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cellsCancer Chemother Pharmacol201065469770619636556
   PubMed Web of Science ®Google Scholar
• AndreFCamponeMO’ReganRPhase I study of everoli-mus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabJ Clin Oncol201028345110511520975068
   PubMed Web of Science ®Google Scholar
• MorrowPKWulfGMEnsorJPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapyJ Clin Oncol201129233126313221730275
   PubMed Web of Science ®Google Scholar
• EichhornPJGiliMScaltritiMPhosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235Cancer Res200868229221923019010894
   PubMed Web of Science ®Google Scholar
• O’BrienNABrowneBCChowLActivated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibMol Cancer Ther2010961489150220501798
   PubMed Web of Science ®Google Scholar
• WangLZhangQZhangJPI3K pathway activation results in low efficacy of both trastuzumab and lapatinibBMC Cancer20111124821676217
   PubMed Web of Science ®Google Scholar
• GayleSSArnoldSLO’ReganRMNahtaRPharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistanceAnticancer Agents Med Chem201212215116222043997
   PubMed Web of Science ®Google Scholar
• ScheuerWFriessTBurtscherHBossenmaierBEndlJHasmannMStrongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor modelsCancer Res200969249330933619934333
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMCLEOPATRA: a phase III evaluation of pertu-zumab and trastuzumab for HER2-positive metastatic breast cancerClin Breast Cancer201010648949121147694
   PubMed Web of Science ®Google Scholar
• CortésJFumoleauPBianchiGVPertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol Epub3 52012
   Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• LoRussoPMWeissDGuardinoEGirishSSliwkowskiMXTrastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerClin Cancer Res201117206437644722003071
   PubMed Web of Science ®Google Scholar
• JunttilaTTLiGParsonsKPhillipsGLSliwkowskiMXTrastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Res Treat2011128234735620730488
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdRugoHSVukeljaSJPhase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyJ Clin Oncol201129439840521172893
   PubMed Web of Science ®Google Scholar
• KropIELoRussoPMillerKA phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy abstract 277035th European Society for Medical Oncology ConferenceOctober 8–12, 2010Milan, Italy
   Google Scholar
• OlsonEMLinNUDiPiroPJResponses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancerAnn Oncol2012231939721531783
   PubMed Web of Science ®Google Scholar
• RabindranSKDiscafaniCMRosfjordECAntitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinaseCancer Res200464113958396515173008
   PubMed Web of Science ®Google Scholar
• HegdePSRusnakDBertiauxMDelineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profilesMol Cancer Ther2007651629164017513611
   PubMed Web of Science ®Google Scholar
• Sánchez-MartínMPandiellaADifferential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implicationsInt J Cancer2011 Epub August 8, 2011
   PubMed Web of Science ®Google Scholar
• SeyhanAAVaradarajanUChoeSA genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsMol Biosyst2011761974198921487605
   PubMedGoogle Scholar
• BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol20102881301130720142587
   PubMed Web of Science ®Google Scholar
• WongKKFracassoPMBukowskiRMA phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsClin Cancer Res20091572552255819318484
   PubMed Web of Science ®Google Scholar
• ZielinskiRLyakhovIJacobsAAffitoxin: a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumorsJ Immunother200932881782519752752
   PubMed Web of Science ®Google Scholar
• ZielinskiRLyakhovIHassanMHER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumorsClin Cancer Res201117155071508121791637
   PubMed Web of Science ®Google Scholar